Global Human Growth Hormone Market
Global Human Growth Hormone Market Size - By Product Type, By Application, By Dosing, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2035
| Published: Jul-2026 | Report ID: HLCA2628 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
According to SPER Market Research, the Global Human Growth Hormone Market is estimated to reach USD 17.38 billion by 2035 with a CAGR 8.77%.
Introduction and Overview
The report includes an in-depth analysis of the Global Human Growth Hormone Market, including market size and trends, product mix, Applications, and supplier analysis.
The global Human Growth Hormone Market was valued at USD 7.5 billion in 2025 and is expected to reach USD 17.38 billion by 2035, registering a CAGR of 8.77% during the forecast period. The Human Growth Hormone Market is driven by the essential role of phosphorus in North America held the largest share of the Human Growth Hormone market in 2025, supported by the rising prevalence of growth hormone deficiencies and increasing demand for effective treatment options. Technological advancements have played a key role in market expansion, with recombinant human growth hormone therapies offering improved safety, purity, and consistent therapeutic outcomes compared to traditional treatments. Innovations such as long-acting formulations, sustained-release injections, auto-injectors, and pre-filled pens have enhanced patient convenience and treatment adherence. Ongoing developments in temperature-stable formulations and non-invasive delivery systems are further reducing treatment burden, improving clinical outcomes, and driving broader acceptance of human growth hormone therapies across the region.
By Product Type:
The branded products segment accounted for the largest revenue share of the Human Growth Hormone market in 2025, supported by strong clinical evidence, trusted product performance, and expanding therapeutic applications. Growth has been driven by increasing diagnoses of pediatric and adult growth hormone deficiency, wider adoption of long-acting formulations, greater use in rare disorders, and improved patient-support programs. Leading branded therapies such as GENOTROPIN, NGENLA, and MiniQuick continue to play a central role in treatment. Meanwhile, the biosimilars segment is expected to record the fastest growth during the forecast period, supported by biologic patent expiries, cost-containment initiatives, streamlined regulatory pathways, and expanding access to affordable, high-quality therapies.
By Application:
The Growth Hormone Deficiency (GHD) segment held the largest share of the Human Growth Hormone market in 2025, supported by its widespread occurrence in both children and adults and its status as the most established indication for growth hormone therapy. Strong clinical evidence, early diagnosis initiatives, structured screening programs, and favorable reimbursement policies have enhanced treatment access and adoption. The long-term nature of GHD treatment contributes to sustained therapy demand. Meanwhile, the idiopathic short stature segment is expected to witness the fastest growth during the forecast period, driven by rising awareness of growth disorders and increasing interest in treatment options.
By Dosing:
The Daily hGH Injection segment accounted for the largest share of the Human Growth Hormone market in 2025, supported by increasing diagnoses of growth hormone deficiency, widespread availability of recombinant therapies, and strong clinical preference for early treatment initiation. Daily injections remain the standard approach for managing both pediatric and adult GHD, ensuring consistent therapeutic outcomes. However, long-term adherence remains a challenge, driving investments in smart injectors and connected monitoring technologies. Meanwhile, the Weekly hGH Injection segment is expected to register the fastest growth during the forecast period, driven by improved convenience, better adherence, and advances in long-acting growth hormone formulations.
By Distribution Channel:
The hospital pharmacy segment held the largest share of the Human Growth Hormone market in 2025, driven by the significant role of hospitals in the diagnosis, initiation, and ongoing management of growth hormone therapy. Specialist supervision, particularly for pediatric and complex adult cases, supports the strong reliance on hospital-based dispensing. Hospital pharmacies are well equipped to handle biologic products, ensuring proper storage and safe distribution. Their close integration with endocrinology departments enables coordinated patient care, while favorable reimbursement policies, direct manufacturer partnerships, and strong patient confidence further reinforce the segment’s leading position in the market.
Regional Insights:
North America led the Human Growth Hormone market in 2025, supported by advanced healthcare infrastructure, high treatment adoption, strong clinical awareness, and the presence of major pharmaceutical companies. The U.S. accounted for the largest regional share, driven by extensive research activities, widespread diagnosis of growth hormone deficiencies, and rapid adoption of innovative therapies. Europe also maintained a significant market position due to robust healthcare systems, established endocrinology networks, and growing use of advanced and biosimilar therapies. Within Europe, the UK and Germany showed steady growth, supported by strong diagnostic capabilities, specialized care, and increasing acceptance of innovative treatment options.
Market Competitive Landscape:
The Global Human Growth Hormone Market is highly consolidated Some of the market key players are Anhui Anke Biotechnology, Ascendis Pharma A/S, Eli Lilly and Company, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, LG Chem, Merck KGaA / EMD Serono, Novo Nordisk A/S, Pfizer Inc., and Sandoz International GmbH (Novartis).
Recent Developments:
- In May 2025, Sandoz launched a new higher-concentration formulation of its biosimilar growth hormone, Omnitrope, in Egypt, enhancing treatment accessibility and providing greater dosing flexibility for children with short stature.
- In August 2024, GeneScience Pharmaceuticals received approval from China's NMPA for a new dosage form of Jintrolong, expanding dosing flexibility and supporting the use of once-weekly PEG-rhGH therapy for patients in China.
Scope of the report:
| Report Metric | Details |
|---|---|
| Market size available for years | 2022-2035 |
| Base year considered | 2025 |
| Forecast period | 2026-2035 |
| Segments covered | By Product Type, By Application, By Dosing, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Anhui Anke Biotechnology, Ascendis Pharma A/S, Eli Lilly and Company, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, LG Chem, Merck KGaA / EMD Serono, Novo Nordisk A/S, Pfizer Inc., and Sandoz International GmbH (Novartis). |
Key Topics Covered in the Report
- Global Human Growth Hormone Market Size (FY’2022-FY’2035)
- Overview of Global Human Growth Hormone Market
- Segmentation of Global Human Growth Hormone Market by Product Type (Branded Products, Biosimilar)
- Segmentation of Global Human Growth Hormone Market by Product Type {Growth Hormone Deficiency (GHD), Adult Growth Hormone Deficiency, Pediatric Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age (SGA), Other Indications}
- Segmentation of Global Human Growth Hormone Market by Dosing Frequency (Daily hGH Injection, Weekly hGH Injection)
- Segmentation of Global Human Growth Hormone Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy)
- Statistical Snap of Global Human Growth Hormone Market
- Expansion Analysis of Global Human Growth Hormone Market
- Problems and Obstacles in Global Human Growth Hormone Market
- Competitive Landscape in the Global Human Growth Hormone Market
- Details on Current Investment in Global Human Growth Hormone Market
- Competitive Analysis of Global Human Growth Hormone Market
- Prominent Players in the Global Human Growth Hormone Market
- SWOT Analysis of Global Human Growth Hormone Market
- Global Human Growth Hormone Market Future Outlook and Projections (FY’2026-FY’2035)
- Recommendations from Analyst
1. Introduction
1.1 Scope of the report1.2 Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary Data2.1.2 Primary Data2.1.3 SPER’s internal Database2.1.4 Primary insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1 Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges
5. Market variable and outlook
5.1 SWOT Analysis
5.1.1 Strengths5.1.2 Weaknesses5.1.3 Opportunities5.1.4 Threats
5.2 PESTEL Analysis
5.2.1 Political Landscape5.2.2 Economic Landscape5.2.3 Social Landscape5.2.4 Technological Landscape5.2.5 Environmental Landscape5.2.6 Legal Landscape
5.3 PORTER’s Five Forces5.4 Heat Map Analysis
6. Competitive Landscape
6.1. Global Human Growth Hormone Market Manufacturing Base Distribution, Sales Area, Product Type6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Human Growth Hormone Market
7. Global Human Growth Hormone Market, By Product Type, (USD Million) 2022-2035
7.1 Branded Products
7.1.1 Norditropin7.1.2 Sogroya7.1.3 Skytrofa7.1.4 Ngenla7.1.5 Other
7.2 Biosimilars
8. Global Human Growth Hormone Market, By Product Type, (USD Million) 2022-2035
8.1 Growth Hormone Deficiency (GHD)8.1.1 Adult Growth Hormone Deficiency8.1.2 Pediatric Growth Hormone Deficiency8.2 Turner Syndrome8.3 Idiopathic Short Stature8.4 Prader-Willi Syndrome8.5 Small for Gestational Age (SGA)8.6 Other Indications
9. Global Human Growth Hormone Market, By Dosing Frequency, (USD Million) 2022-2035
9.1 Daily hGH Injection9.2 Weekly hGH Injection
10. Global Human Growth Hormone Market, By Distribution Channel, (USD Million) 2022-2035
10.1 Hospital Pharmacy10.2 Retail Pharmacy10.3 Online Pharmacy10.4 Specialty Pharmacy
11. Global Human Growth Hormone Market, (USD Million) 2022-2035
11.1 Global Human Growth Hormone Market Size and Market Share
12. Global Human Growth Hormone Market, By Region, (USD Million) 2022-2035
12.1 Asia-Pacific
12.1.1 Australia12.1.2 China12.1.3 India12.1.4 Japan12.1.5 South Korea12.1.6 Rest of Asia-Pacific
12.2 Europe
12.2.1 France12.2.2 Germany12.2.3 Italy12.2.4 Spain12.2.5 United Kingdom12.2.6 Rest of Europe
12.3 Middle East and Africa
12.3.1 Kingdom of Saudi Arabia12.3.2 United Arab Emirates12.3.3 Qatar12.3.4 South Africa12.3.5 Egypt12.3.6 Morocco12.3.7 Nigeria12.3.8 Rest of Middle-East and Africa
12.4 North America
12.4.1 Canada12.4.2 Mexico12.4.3 United States
12.5 Latin America
12.5.1 Argentina12.5.2 Brazil12.5.3 Rest of America
13. Company Profile
13.1 Anhui Anke Biotechnology
13.1.1 Company details13.1.2 Financial outlook13.1.3 Product summary13.1.4 Recent developments
13.2 Ascendis Pharma A/S
13.2.1 Company details13.2.2 Financial outlook13.2.3 Product summary13.2.4 Recent developments
13.3 Eli Lilly and Company
13.3.1 Company details13.3.2 Financial outlook13.3.3 Product summary13.3.4 Recent developments
13.4 Ferring Pharmaceuticals
13.4.1 Company details13.4.2 Financial outlook13.4.3 Product summary13.4.4 Recent developments
13.5 GeneScience Pharmaceuticals
13.5.1 Company details13.5.2 Financial outlook13.5.3 Product summary13.5.4 Recent developments
13.6 LG Chem
13.6.1 Company details13.6.2 Financial outlook13.6.3 Product summary13.6.4 Recent developments
13.7 Merck KGaA / EMD Serono
13.7.1 Company details13.7.2 Financial outlook13.7.3 Product summary13.7.4 Recent developments
13.8 Novo Nordisk A/S
13.8.1 Company details13.8.2 Financial outlook13.8.3 Product summary13.8.4 Recent developments
13.9 Pfizer Inc.
13.9.1 Company details13.9.2 Financial outlook13.9.3 Product summary13.9.4 Recent developments
13.10 Sandoz International GmbH (Novartis)
13.10.1 Company details13.10.2 Financial outlook13.10.3 Product summary13.10.4 Recent developments
13.11 Others
14. Conclusion
15. List Of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
